List view / Grid view
This exclusive ebook takes an in-depth look at recent developments in the field of cancer immunotherapy, with expert interviews exploring how researchers are advancing next-generation cell therapies into the clinic.
The scientists found the mechanism of drug resistance depends on activation of a protein called KDM1B which controls and regulates gene expression.
Researchers at the University of Arizona Health Sciences found that CD4 plays an active role in regulating T-cell receptor signalling.
Discover why the Hyperion+ Imaging System is the standard to assess tumour-immune interactions and get deep single-cell insights.
A report has shown that the immuno-oncology drug discovery outsourcing market is set to be worth $2563 million by 2030.
While the introduction of novel immunotherapies to combat and treat cancer has advanced patient care greatly, ever more effective solutions continue to be required. Here, Dr Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haemato-Oncology at Janssen Europe, Middle East & Africa (EMEA), explores how T-cell redirecting bispecific antibodies (TRBAs)…
In this ebook are articles on why monoclonal antibodies represent a high level of promise in the fight against cancer and how T-cell redirecting bispecific antibodies could work as a new immunotherapeutic strategy against haematological conditions.
A new high-throughput approach has shown how patients whose tumours express CD58 are more likely to respond to CAR T-cell therapy.
Researchers have found how tumours can avoid the immune system and cancer immunotherapies, including CAR T-cell therapies.
The approach mimics the physical forces exerted by T cells as they crawl over host cells, could help scientists develop more effective cancer immunotherapies.
A new study has shown that lactate, a metabolic byproduct produced during exercise, could augment current cancer immunotherapies.
Researchers have revealed the immune landscape and microbiome of pancreatic cysts as they progress to pancreatic cancer, providing targets for immunotherapy.
New study finds that using CRISPR to block RASA2 gene makes T cells more resilient against cancer.
Scientists have discovered adenosine could inhibit CD39, a molecule that suppresses the immune system.
The study describes how oncolytic virotherapy can work with existing immunotherapy techniques, boosting the immune capacity to effectively target and destroy cancer cells.
